1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Shares are up ~54% YTD as Evommune advances two clinical-stage candidates: EVO756 (phase 2b for chronic spontaneous urticaria and atopic dermatitis; urticaria top-line in Q2, atopic dermatitis in Q3/Q4) and EVO301 (mid-stage atopic dermatitis trial met primary endpoint with 55% EASI reduction vs 22% placebo at 12 weeks; phase 2 for ulcerative colitis planned). William Blair projects EVO756 could reach $5 billion peak sales by 2035; recent sector M&A precedent (Incyte paid $750M for Escient) heightens takeover/partnership speculation. Financials: $216.7M cash at end-2025 (up from $72M end-2024) with runway into 2028, 2025 revenue $13M, and a $68.9M net loss in 2025; market cap roughly $835M, implying high volatility and binary risk/reward.

Analysis

Evommune's platform creates an asymmetric payoff: a single positive clinical readout or a strategic partnership could transfer outsized value to a small-cap balance sheet, while negative data mostly destroys optionality. That asymmetry will compress tradeable windows into tight, high-volatility event periods where implied vols spike and liquidity thins, magnifying move sizes relative to fundamentals.

A successful validation of the mechanism would produce immediate M&A momentum from specialty and mid-cap pharma buyers looking to plug inflammation pipelines, and a second-order surge in demand for specific CRO/CMO capabilities (e.g., GLP tox, formulation scale-up for dermatology/gastroenterology routes). Conversely, a safety or reproducibility issue would not only impair the company but could chill investor appetite across the nascent MRGPRX2/MRGP-targeting subspace, lowering acquisition multiples for adjacent targets.

For portfolio construction, treat exposure as event-driven small-binary risk: position sizes should be measured, hedged, and option-centric to define loss while leaving upside asymmetric. If a positive result triggers suitors, expect a narrow window to monetize via structured exit (calls/stock) before deal chatter lifts the spread; if negative, the downside is rapid and deep, arguing for protective structures rather than naked equity punts.

Key Decisions for Investors

• Buy EVMN defined-risk long call spread (3–6 month expiry) sized to 0.25% of NAV. Target a 2.5–3x payoff if the near-term catalyst is positive; maximum loss = premium paid. Rationale: capture binary upside while limiting capital at risk during high IV.
• Initiate a small equity stake in EVMN (0.5% NAV) hedged with protective puts (30–45 day tenor) to cap downside ahead of catalysts. If readouts are positive, convert puts into covered-call collars to monetize a 40–100% rally within 3–9 months.
• Event-driven pair: long EVMN / short INCY sized 0.2% NAV each as a hedge against sectorwide mover risk. Rationale: isolate idiosyncratic upside from a buyout bid for EVMN while partially offsetting biotech-sector volatility; set stop-loss at 25% adverse move in the pair.
• If a positive clinical signal materializes, be ready to sell into the immediacy of M&A flow: take profits by selling 6–12 month covered calls or entering a takeover-arbitrage hedge if an offer appears. Target crystallizing 50–70% of position gains within 2–6 weeks of official partner discussions to avoid post-announcement mean reversion.